References
- Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoeconomics Outcomes Res.10(3), 239–245 (2010).
- Bridges J, Onukwugha E, Mullins D. Healthcare rationing by proxy. Cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics28, 175–184 (2010).
- Usher C, Tilson L, Olsen J et al. Cost effectiveness of HPV vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 & 18 using a transmission dynamic model. Vaccine26, 5654–5661 (2008).
- Stafinski T, McCabe C, Menon D. Funding the unfundable. Mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics28, 113–142 (2010).
- Hughes D, Ferner R. New drugs for old: disinvestment and NICE. BMJ340, C572 (2010).
Websites
- Layte R, Barry M, Bennett K et al. Projecting the impact of demographic change on the demand for and delivery of healthcare in Ireland. Research series number 13 (2009) www.esri.ie/UserFiles/publications/20091023164031/RS013.pdf (Accessed March 2010)
- National Centre for Pharmacoeconomics. A review of the cost-effectiveness of sunitinib (Sutent®) under the High Tech Drug Scheme in Ireland. October 2006 www.ncpe.ie/u_docs/doc_129.pdf (Accessed April 2010)
- National Centre for Pharmacoeconomics. Economic evaluation of agomelatine (Valdoxan®) for the treatment of major depressive disorder. September 2009 www.ncpe.ie/u_docs/doc_176.pdf (Accessed April 2010)
- Health Information and Quality Authority. Health technology assessment of the role of human papillomavirus vaccines in reducing the risk of cervical cancer in Ireland (2008) www.hiqa.ie (Accessed March 2010)
- National Centre for Pharmacoeconomics. An economic evaluation of eculizumab (Soliris®) for the treatment of paroxysmal noctural haemoglobinuria (PNH) in the Irish healthcare setting. March 2010 www.ncpe.ie/u_docs/doc_188.pdf (Accessed March 2010)
- Department of Health and Children. Economies in drug usage in the Irish healthcare setting (2009) www.dohc.ie (Accessed June 2009)
- National Centre for Pharmacoeconomics. Economic evalution of glucosamine sulfate (DONA®) for the treatment of oestoarthritis in the Irish Healthcare setting. June 2009 www.ncpe.ie/u_docs/doc_171.pdf (Accessed March 2010)